Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Xtandi“
Suchtreffer
Begriffe & Kennungen
Xtandi
Eintrag öffnenXtandi · 4.1 Therapeutic indications · 1
Eintrag öffnenXtandi · 4.1 Therapeutic indications · 2
Eintrag öffnenXtandi · 4.3 Contraindications · 1
Eintrag öffnenXtandi · 4.3 Contraindications · 2
Eintrag öffnenXtandi · 4.3 · Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. Women who are o
Eintrag öffnenXtandi · 4.3 · Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. Women who are o
Eintrag öffnenXtandi · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenXtandi · 4.4 Special warnings and precautions for use · 2
Eintrag öffnenXtandi · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenXtandi · 4.5 Interaction with other medicinal products and other forms of interaction · 2
Eintrag öffnenXtandi · 4.5 · 35 Potential for enzalutamide to affect exposures to other medicinal products
Eintrag öffnenXtandi · 4.5 · 36 persist for one month or longer after stopping enzalutamide. A gradual dose reduction of the concomitant me
Eintrag öffnenXtandi · 4.5 · 5 Potential for enzalutamide to affect exposures to other medicinal products
Eintrag öffnenXtandi · 4.5 · 6 persist for one month or longer after stopping enzalutamide. A gradual dose reduction of the concomitant med
Eintrag öffnenXtandi · 4.5 · BCRP substrates At steady-state, enzalutamide did not cause a clinically meaningful change in exposure to the
Eintrag öffnenXtandi · 4.5 · BCRP substrates At steady-state, enzalutamide did not cause a clinically meaningful change in exposure to the
Eintrag öffnenXtandi · 4.5 · CYP1A2 and CYP2C8 substrates Enzalutamide (160 mg once daily) did not cause a clinically relevant change in th
Eintrag öffnenXtandi · 4.5 · CYP1A2 and CYP2C8 substrates Enzalutamide (160 mg once daily) did not cause a clinically relevant change in th
Eintrag öffnenXtandi · 4.5 · CYP2C8 and CYP3A4 inducers Following oral administration of the moderate CYP2C8 and strong CYP3A4 inducer rifa
Eintrag öffnen